Back

Oral PCSK9 inhibitors

30 August 2026 (17:54 - 18:06)
Organised by: Logo
Congress Presentation Part of: Present and the future of PCSK9 inhibition in cardiovascular prevention: from antibodies to gene editing Risk Factors and Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

4 More presentations in this session

Presentation thumbnail
The discovery of PCSK9
Professor C. Boileau (Paris, FR)
Slides Video
Presentation thumbnail
The present: antibodies siRNAs
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
The future: gene editing
Professor A. Zeiher (Frankfurt, DE)
Slides Video
Presentation thumbnail
Present and the future of PCSK9 inhibition in cardiovascular prevention: from antibodies to gene editing - discussion
Video

Access the full session

Session thumbnail
Present and the future of PCSK9 inhibition in cardiovascular prevention: from antibodies to gene editing
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:54 CET
You may be interested in
thumbnail
Congress Presentation
Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis
29 August 2025
thumbnail
Congress Presentation
State-of-the-art lecture on next generation cardiometabolic pharmacology: from lipids to RNA therapeutics
28 August 2026
thumbnail
Congress Presentation
Preclinical study and evaluation of S016, a novel oral small-molecule PCSK9 inhibitor
30 August 2026
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources